Hemlibra was found to ease pain and improve quality of life for hemophilia A patients, even those with long-term joint damage ...

Roche has reported a 7% increase in full-year 2024 sales at constant exchange rates (CER), reaching CHF 60.5bn ($66.9bn). The ...

Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...

The subcutaneous injection drug emicizumab (Hemlibra), for instance, greatly reduces bleeding in hemophilia A, the most common form of this bleeding disorder. Ben Samelson-Jones, MD, PhD “It’s ...

The app lets patients track their infusions, bleeds, pain, and activities, and helps them manage their medication stock. The efficacy and safety profiles of preventive treatment with Hemlibra ...

Emicizumab has been approved for the treatment of patients with acquired hemophilia A in Japan, but this use has not been approved in the United States by the FDA. In patients with acquired hemophilia ...

While Roche is still involved in cancer drugs, it is diversifying into other disease areas and has targeted the haemophilia market with Hemlibra (emicizumab). With this new indication, Hemlibra is ...